Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–10 of 10 results
Advanced filters: Author: Edward K. Geissler Clear advanced filters

  • Immune disease-associated biomarker values are commonly more variable in affected compared to unaffected patient populations, which limits a biomarker’s informative range. Here, the authors formalise a computational solution that splits datasets into informative and uninformative subsets to improve biomarker discovery and performance of multivariate predictive models.

    • Gunther Glehr
    • Paloma Riquelme
    • James A. Hutchinson
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-21

  • Biochemical and lipidomic analyses identify an anti-ferroptotic function of vitamin K and reveal ferroptosis suppressor protein 1 (FSP1) as the enzyme mediating warfarin-resistant vitamin K reduction in the canonical vitamin K cycle.

    • Eikan Mishima
    • Junya Ito
    • Marcus Conrad
    ResearchOpen Access
    Nature
    Volume: 608, P: 778-783

  • Checkpoint blocking therapies are used to treat metastatic melanoma, but can have adverse immune-mediated effects, including liver pathology. Here the authors identify an expanded pool of CD4+ effector memory T cells resulting from prior CMV exposure as a risk factor for this adverse effect in these patients.

    • James A. Hutchinson
    • Katharina Kronenberg
    • Sebastian Haferkamp
    ResearchOpen Access
    Nature Communications
    Volume: 12, P: 1-15

  • Non-melanoma skin cancer occurs at an alarmingly high rate in transplant recipients, causing considerable morbidity and sometimes even mortality. A recent prospective clinical study performed by nephrologists and dermatologists at the Johann Wolfgang Goethe University in Frankfurt suggests that switching renal transplant recipients with skin lesions onto the mTOR inhibitor sirolimus might keep non-melanoma skin cancer in check.

    • Edward K. Geissler
    • Hans J. Schlitt
    News & Views
    Nature Reviews Nephrology
    Volume: 6, P: 639-641

  • Regulatory macrophages (Mreg) can directly suppress T effector cell responses. Here the authors show that human Mreg also elicit TIGIT+ regulatory T cells by integrating multiple differentiation signals, and that donor Mreg-induced recipient Tregs may promote kidney transplant acceptance in patients.

    • Paloma Riquelme
    • Jan Haarer
    • James A. Hutchinson
    ResearchOpen Access
    Nature Communications
    Volume: 9, P: 1-18

  • Ferroptosis is a form of non-apoptotic cell death with unclear physiological relevance. Conrad and colleagues now report that unrestrained ferroptosis can lead to renal failure. They also identify a small molecule that limits ferroptosis in vivo.

    • Jose Pedro Friedmann Angeli
    • Manuela Schneider
    • Marcus Conrad
    Research
    Nature Cell Biology
    Volume: 16, P: 1180-1191

  • The incidence of cancer in transplant recipients is indisputably higher than that of the age-matched general population, and the increased cancer development in transplant recipients who require immunosuppression to avoid graft rejection is well recognized. This Review discusses the advances with mTOR inhibitors that interfere with tumour development via immune and non-immune mechanisms, and the current and future perspectives on how best to normalize the unacceptably high rates of post-transplantation malignancies are highlighted.

    • Edward K. Geissler
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 12, P: 705-717